OBJECTIVE: @entity5 affects many aspects of @entity5 , including proliferation and survival of malignant cells, angiogenesis, and therapeutic response. Some biomarkers representing the degree of systemic @entity32 , such as the Glasgow prognostic score, NLR and PLR, have been shown to have prognostic value in many kinds of @entity5 @entity1 . Aim of this study to investigate to compare neutrophil/leukocyte (NLR) and platelet/lymphocyte (PLR) ratios of the @entity1 with @entity1127 and @entity14 ( @entity14 ) and tried to determine whether this could be used as a biomarker in follow up of the @entity1 with @entity1127 . @entity1 AND METHODS: A total of 100 @entity14 and 124 healthy controls were included in the study. Exculusion criteria were endocrinologic or @entity209 , @entity697 , @entity101 and @entity731 , @entity8 . Blood count parameters of the @entity1 were measured. The NLR was calculated as a simple ratio between the absolute neutrophil and the absolute lymphocyte counts. The PLR was defined as the platelet counts to lymphocyte ratio. RESULTS: A statistically significant difference was not detected between Group A and C with regard to NLR and PLR. NLR and PLR were found statistically significantly high in Group B ( @entity14 ), Group A ( @entity1127 ) and Group C (healthy individuals) (p < 0.001 and p < 0.001). Our study showed that the optimum NLR cut-off point for @entity1127 was 2.28 (sensitivity: 68.7%, specificity: 42.3%). When the sensitivity and specificity levels of the PLR were assessed, they were 68.7% and 46.5% for @entity1127 , 80% and 68.9% for @entity14 . CONCLUSIONS: NLR and PLR may be used for follow up conversion of @entity1586 to invasive @entity5 .

Comparison of XXXX and adenocarcinoma with regard to NLR and PLR.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal diseases'] @entity697 :: ('MESH:D000208', 'Disease') :: ['acute or chronic diseases'] @entity1127 :: ('MESH:D011127', 'Disease') :: ['colorectal neoplastic polyps', 'neoplastic polyps', 'colorectal polyp'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'Cancer-related inflammation', 'malignancy'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal polyps, 113 colorectal cancers', 'CRC', 'colorectal cancer'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic diseases'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic heart diseases'] @entity1586 :: ('MESH:D003111', 'Disease') :: ['colonic and rectal neoplastic polyps']
@entity1127 :: (MESH:D011127,Disease) :: ['colorectal neoplastic polyps']
